Fill out this form to email this article to a friend
Talk of the bay
After delay, drug company ready again to go public
By HELEN HUNTLEY
Published July 18, 2005
Look for an initial public offering this week from Accentia Biopharmaceuticals. The Tampa company was hoping to take the public plunge earlier this month, but delayed the offering to reprint its registration document, what brokers call a "red herring."
The reason for the reprint is to include recent good news from the U.S. Food and Drug Administration. The FDA has accepted Accentia's investigational new drug application for SinuNase, and the company plans to begin Phase III trials for the drug to treat chronic sinusitis. The company is in Phase III trials for a lymphoma drug, Biovaxid.
Accentia hopes the offering will bring it net proceeds of $41.2-million to continue product development and pay other expenses. The company lost $28.5-million on net sales of $25.9-million last fiscal year. Its two largest customers, Cardinal Health and McKesson Corp., account for nearly a third of its sales.
- , Times staff writer
[Last modified July 15, 2005, 17:37:02]
Share your thoughts on this story
|
News
Fifty years ago, they were screwed-up kids sent to the Florida School for Boys to be straightened out. But now they are screwed-up men, scarred by the whippings they endured. Read the story and see a video and portrait gallery.
Print
Email story
Comment
Email editor
